#CROI25: Mer­ck’s trou­bled HIV drug heads to reg­u­la­tors; Vi­iV seeks longer-act­ing HIV treat­ment

Here are some of the most com­pelling HIV up­dates from the an­nu­al Con­fer­ence on Retro­virus­es and Op­por­tunis­tic In­fec­tions in San Fran­cis­co:

Mer­ck de­tails Phase 3 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER